These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 26234904)

  • 21. Design and Identification of a GPR40 Full Agonist (
    Furukawa H; Miyamoto Y; Hirata Y; Watanabe K; Hitomi Y; Yoshitomi Y; Aida J; Noguchi N; Takakura N; Takami K; Miwatashi S; Hirozane Y; Hamada T; Ito R; Ookawara M; Moritoh Y; Watanabe M; Maekawa T
    J Med Chem; 2020 Sep; 63(18):10352-10379. PubMed ID: 32900194
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of TAK-875: A Potent, Selective, and Orally Bioavailable GPR40 Agonist.
    Negoro N; Sasaki S; Mikami S; Ito M; Suzuki M; Tsujihata Y; Ito R; Harada A; Takeuchi K; Suzuki N; Miyazaki J; Santou T; Odani T; Kanzaki N; Funami M; Tanaka T; Kogame A; Matsunaga S; Yasuma T; Momose Y
    ACS Med Chem Lett; 2010 Sep; 1(6):290-4. PubMed ID: 24900210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term in vitro treatment of INS-1 rat pancreatic β-cells by unsaturated free fatty acids protects cells against gluco- and lipotoxicities via activation of GPR40 receptors.
    Tuo Y; Feng DD; Wang DF; Sun J; Li SB; Chen C
    Clin Exp Pharmacol Physiol; 2012 May; 39(5):423-8. PubMed ID: 22332921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of Pyrrolidine-Containing GPR40 Agonists: Stereochemistry Effects a Change in Binding Mode.
    Jurica EA; Wu X; Williams KN; Hernandez AS; Nirschl DS; Rampulla RA; Mathur A; Zhou M; Cao G; Xie C; Jacob B; Cai H; Wang T; Murphy BJ; Liu H; Xu C; Kunselman LK; Hicks MB; Sun Q; Schnur DM; Sitkoff DF; Dierks EA; Apedo A; Moore DB; Foster KA; Cvijic ME; Panemangalore R; Flynn NA; Maxwell BD; Hong Y; Tian Y; Wilkes JJ; Zinker BA; Whaley JM; Barrish JC; Robl JA; Ewing WR; Ellsworth BA
    J Med Chem; 2017 Feb; 60(4):1417-1431. PubMed ID: 28112924
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Discovery of a novel series of indoline carbamate and indolinylpyrimidine derivatives as potent GPR119 agonists.
    Sato K; Sugimoto H; Rikimaru K; Imoto H; Kamaura M; Negoro N; Tsujihata Y; Miyashita H; Odani T; Murata T
    Bioorg Med Chem; 2014 Mar; 22(5):1649-66. PubMed ID: 24508142
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of novel orally bioavailable GPR40 agonists.
    Lu H; Fei H; Yang F; Zheng S; Hu Q; Zhang L; Yuan J; Feng J; Sun P; Dong Q
    Bioorg Med Chem Lett; 2013 May; 23(10):2920-4. PubMed ID: 23582779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of novel benzo[b]thiophene tetrazoles as non-carboxylate GPR40 agonists.
    Huang H; Winters MP; Meegalla SK; Arnoult E; Paul Lee S; Zhao S; Martin T; Rady B; Liu J; Towers M; Otieno M; Xu F; Lim HK; Silva J; Pocai A; Player MR
    Bioorg Med Chem Lett; 2018 Feb; 28(3):429-436. PubMed ID: 29258772
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119.
    Wacker DA; Wang Y; Broekema M; Rossi K; O'Connor S; Hong Z; Wu G; Malmstrom SE; Hung CP; LaMarre L; Chimalakonda A; Zhang L; Xin L; Cai H; Chu C; Boehm S; Zalaznick J; Ponticiello R; Sereda L; Han SP; Zebo R; Zinker B; Luk CE; Wong R; Everlof G; Li YX; Wu CK; Lee M; Griffen S; Miller KJ; Krupinski J; Robl JA
    J Med Chem; 2014 Sep; 57(18):7499-508. PubMed ID: 25208139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 3-Substituted 3-(4-aryloxyaryl)-propanoic acids as GPR40 agonists.
    Walsh SP; Severino A; Zhou C; He J; Liang GB; Tan CP; Cao J; Eiermann GJ; Xu L; Salituro G; Howard AD; Mills SG; Yang L
    Bioorg Med Chem Lett; 2011 Jun; 21(11):3390-4. PubMed ID: 21514824
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Physiology and therapeutics of the free fatty acid receptor GPR40.
    Huang H; Dai MH; Tao YX
    Prog Mol Biol Transl Sci; 2014; 121():67-94. PubMed ID: 24373235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel agonists of free fatty acid receptor 1 (GPR40) based on 3-(1,3,4-thiadiazol-2-yl)propanoic acid scaffold.
    Krasavin M; Lukin A; Zhurilo N; Kovalenko A; Zahanich I; Zozulya S
    J Enzyme Inhib Med Chem; 2016 Dec; 31(6):1404-10. PubMed ID: 26899762
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of Potent and Orally Bioavailable Dihydropyrazole GPR40 Agonists.
    Shi J; Gu Z; Jurica EA; Wu X; Haque LE; Williams KN; Hernandez AS; Hong Z; Gao Q; Dabros M; Davulcu AH; Mathur A; Rampulla RA; Gupta AK; Jayaram R; Apedo A; Moore DB; Liu H; Kunselman LK; Brady EJ; Wilkes JJ; Zinker BA; Cai H; Shu YZ; Sun Q; Dierks EA; Foster KA; Xu C; Wang T; Panemangalore R; Cvijic ME; Xie C; Cao GG; Zhou M; Krupinski J; Whaley JM; Robl JA; Ewing WR; Ellsworth BA
    J Med Chem; 2018 Feb; 61(3):681-694. PubMed ID: 29316397
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Current status of clinical development of novel anti-diabetic drugs].
    Kamiyama H; Terauchi Y
    Nihon Rinsho; 2015 Mar; 73(3):517-22. PubMed ID: 25812383
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CoMSIA study on substituted aryl alkanoic acid analogs as GPR40 agonists.
    Bhatt A; Patel PD; Patel MR; Singh S; Lau-Cam CA; Talele TT
    Chem Biol Drug Des; 2011 May; 77(5):361-72. PubMed ID: 21352503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of a potent and selective free fatty acid receptor 1 agonist with low lipophilicity and high oral bioavailability.
    Christiansen E; Due-Hansen ME; Urban C; Grundmann M; Schmidt J; Hansen SV; Hudson BD; Zaibi M; Markussen SB; Hagesaether E; Milligan G; Cawthorne MA; Kostenis E; Kassack MU; Ulven T
    J Med Chem; 2013 Feb; 56(3):982-92. PubMed ID: 23294321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery and biological evaluation of novel 4-amino-2-phenylpyrimidine derivatives as potent and orally active GPR119 agonists.
    Negoro K; Yonetoku Y; Misawa-Mukai H; Hamaguchi W; Maruyama T; Yoshida S; Takeuchi M; Ohta M
    Bioorg Med Chem; 2012 Sep; 20(17):5235-46. PubMed ID: 22836190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of 6,7-dihydro-5H-pyrrolo[2,3-a]pyrimidines as orally available G protein-coupled receptor 119 agonists.
    Katamreddy SR; Carpenter AJ; Ammala CE; Boros EE; Brashear RL; Briscoe CP; Bullard SR; Caldwell RD; Conlee CR; Croom DK; Hart SM; Heyer DO; Johnson PR; Kashatus JA; Minick DJ; Peckham GE; Ross SA; Roller SG; Samano VA; Sauls HR; Tadepalli SM; Thompson JB; Xu Y; Way JM
    J Med Chem; 2012 Dec; 55(24):10972-94. PubMed ID: 23214471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progress in the discovery and development of small-molecule modulators of G-protein-coupled receptor 40 (GPR40/FFA1/FFAR1): an emerging target for type 2 diabetes.
    Bharate SB; Nemmani KV; Vishwakarma RA
    Expert Opin Ther Pat; 2009 Feb; 19(2):237-64. PubMed ID: 19441920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design and Synthesis of Novel, Selective GPR40 AgoPAMs.
    Plummer CW; Clements MJ; Chen H; Rajagopalan M; Josien H; Hagmann WK; Miller M; Trujillo ME; Kirkland M; Kosinski D; Mane J; Pachanski M; Cheewatrakoolpong B; Nolting AF; Orr R; Christensen M; Campeau LC; Wright MJ; Bugianesi R; Souza S; Zhang X; Di Salvo J; Weinglass AB; Tschirret-Guth R; Nargund R; Howard AD; Colletti SL
    ACS Med Chem Lett; 2017 Feb; 8(2):221-226. PubMed ID: 28197316
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist.
    Brown SP; Dransfield PJ; Vimolratana M; Jiao X; Zhu L; Pattaropong V; Sun Y; Liu J; Luo J; Zhang J; Wong S; Zhuang R; Guo Q; Li F; Medina JC; Swaminath G; Lin DC; Houze JB
    ACS Med Chem Lett; 2012 Sep; 3(9):726-30. PubMed ID: 24900539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.